Potent and selective Rho-kinase inhibitor (IC50 values are 3 and 56 nM for ROCK-II and ROCK-I respectively).
Feng et al (2008) Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors. J.Med.Chem. 51 6642 PMID:18834107
Zonisamide-13C2,15N is intended for use as an internal standard for the quantification of zonisamide by GC- or LC-MS. Zonisamide (T0267) is an antiepileptic agent.1 It selectively inhibits the repeated firing of sodium channels (IC50 = 2 μg/ml)in mouse embryo spinal cord neurons and inhibits spontaneous channel firing when used at concentrations greater than 10 μg/ml.2 In rat cerebral cortex neurons,zonisamide (1-1,000 μM)inhibits T-type calcium channels with a maximum reduction of 60% of the calcium current.3 Zonisamide (T0267)inhibits H. pylori recombinant carbonic anhydrase (CA)and the human CA isoforms I,II,and V with Ki values of 218,56,35,and 21 nM,respectively.4,5 In mice,it has anticonvulsant activity against maximal electroshock seizure (MES)and pentylenetetrazole-induced maximal,but not minimal,seizures (ED50s = 19.6,9.3,and >500 mg/kg,respectively). Zonisamide (T0267) (40 mg/kg,p.o.)prevents MPTP-induced decreases in the levels of dopamine ,but not homovanillic acid or dihydroxyphenyl acetic acid ,and increases MPTP-induced decreases in the dopamine turnover rate in mouse striatum in a model of Parkinson's disease.6 Formulations containing zonisamide have been used in the treatment of partial seizures in adults with epilepsy.
HSD1590 is a highly effective and potent inhibitor of ROCK1 and ROCK2, with IC50 values of 1.22 nM and 0.51 nM, respectively. It demonstrates exceptional binding affinity to ROCK, with Kd values below 2 nM. Moreover, HSD1590 showcases minimal cytotoxicity, making it an ideal compound for various applications.
Rho-Kinase-IN-2 (Compound 23) is an orally active and selective inhibitor of Rho Kinase (ROCK), which can penetrate the central nervous system (CNS). It exhibits a high affinity for ROCK2 with an inhibition constant (IC50) of 3 nM. This compound is of potential interest for further investigations in the field of Huntington's disease research [1].
Nocarnickelamides B (Compound 2) 是一种线性肽类ROCK1/2抑制剂,对ROCK1和ROCK2的IC50值分别为14.9 μM和21.9 μM。其通过结合于ATP结合位点发挥作用,抑制ROCK调控的细胞骨架收缩标志物(如肌球蛋白轻链的激活)。Nocarnickelamides B 在青光眼研究中具备应用潜力。